 |
The Journal of Neuroscience, March 30, 2005, 25(13):3469-3477; doi:10.1523/JNEUROSCI.0105-05.2005
Previous Article | Next Article 
Neurobiology of Disease
Neurodegenerative Illness in Transgenic Mice Expressing a Transmembrane Form of the Prion Protein
Richard S. Stewart,1
Pedro Piccardo,2,3
Bernardino Ghetti,2 and
David A. Harris1
1Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri 63110, 2Division of Neuropathology, Indiana University School of Medicine, Indianapolis, Indiana 46202, and 3Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20852
Although PrPSc is thought to be the infectious form of the prion protein, it may not be the form that is responsible for neuronal cell death in prion diseases. CtmPrP is a transmembrane version of the prion protein that has been proposed to be a neurotoxic intermediate underlying prion-induced pathogenesis. To investigate this hypothesis, we have constructed transgenic mice that express L9R-3AV PrP, a mutant prion protein that is synthesized exclusively in the CtmPrP form in transfected cells. These mice develop a fatal neurological illness characterized by ataxia and marked neuronal loss in the cerebellum and hippocampus. CtmPrP in neurons cultured from transgenic mice is localized to the Golgi apparatus, rather than to the endoplasmic reticulum as in transfected cell lines. Surprisingly, development of the neurodegenerative phenotype is strongly dependent on coexpression of endogenous, wild-type PrP. Our results provide new insights into the cell biology of CtmPrP, the mechanism by which it induces neurodegeneration, and possible cellular activities of PrPC.
Key words: prion; transgenic; neurodegeneration; Golgi; transmembrane; mutation
Received Oct 29, 2004;
revised February 15, 2005;
accepted February 16, 2005.
This article has been cited by other articles:

|
 |

|
 |
 
S. Hornemann, C. von Schroetter, F. F. Damberger, and K. Wuthrich
Prion Protein-Detergent Micelle Interactions Studied by NMR in Solution
J. Biol. Chem.,
August 21, 2009;
284(34):
22713 - 22721.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Linden, V. R. Martins, M. A. M. Prado, M. Cammarota, I. Izquierdo, and R. R. Brentani
Physiology of the Prion Protein
Physiol Rev,
April 1, 2008;
88(2):
673 - 728.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. G. Kovacs and H. Budka
Prion Diseases: From Protein to Cell Pathology
Am. J. Pathol.,
March 1, 2008;
172(3):
555 - 565.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. M. Barron, S. L. Campbell, D. King, A. Bellon, K. E. Chapman, R. A. Williamson, and J. C. Manson
High Titers of Transmissible Spongiform Encephalopathy Infectivity Associated with Extremely Low Levels of PrPSc in Vivo
J. Biol. Chem.,
December 7, 2007;
282(49):
35878 - 35886.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Orsi, L. Fioriti, R. Chiesa, and R. Sitia
Conditions of Endoplasmic Reticulum Stress Favor the Accumulation of Cytosolic Prion Protein
J. Biol. Chem.,
October 13, 2006;
281(41):
30431 - 30438.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. S. Rambold, M. Miesbauer, D. Rapaport, T. Bartke, M. Baier, K. F. Winklhofer, and J. Tatzelt
Association of Bcl-2 with Misfolded Prion Protein Is Linked to the Toxic Potential of Cytosolic PrP
Mol. Biol. Cell,
August 1, 2006;
17(8):
3356 - 3368.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Gu, X. Luo, S. Basu, H. Fujioka, and N. Singh
Cell-specific metabolism and pathogenesis of transmembrane prion protein.
Mol. Cell. Biol.,
April 1, 2006;
26(7):
2697 - 2715.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|

|